CRISPR and Sickle Cell Disease (SCD)

There are currently four clinical-stage gene-editing candidates in clinical trials for sickle cell disease, which affects millions of people worldwide...

Editas Medicine recently announced positive initial safety and efficacy data for its CRISPR-edited cell therapy EDIT-301. The data was obtained from...

In this clinical update, we look at recent advances in two clinical-stage gene-editing programmes. Editas Medicine's sickle cell disease candidate...

Graphite Bio reports dosing the first patient with its lead CRISPR therapy candidate nula-cel in Phase 1/2 trial for sickle cell disease.

Last week, Editas Medicine announced successful engraftment of the first patient dosed with the CRISPR-based therapeutic candidate EDIT-301 for the...

This week's clinical update includes news from Allogene Therapeutics and Graphite Bio. The U.S. Food and Drug Administration (FDA) recently granted...

This clinical update looks at Graphite Bio's sickle cell disease candidate GPH101. GPH101 is an ex vivo CRISPR-edited cell therapy that is anticipated...

In 2022, we celebrate a decade of CRISPR as a game-changing tool in research and medicine. The last 10 years have been phenomenal, and CRISPR cures...